❤️Can Fasting Redefine Heart Disease ? infology

Fasting and heart health in 2026: evidence-based insights on whether it can truly improve cardiovascular outcomes or simply support a healthy lifestyle.

A condensed, visual synthesis of four landmark 2026 trials and fasting science — every key finding, mechanism, FAQ, and safety protocol on one reference document.

25%

MACE Reduction

VESALIUS-CV

57%

LDL-C Reduction

Enlicitide — Oral PCSK9i

85%

Pancreatitis Risk ↓

Olezarsen — CORE-TIMI 72

4–8 mmHg

Systolic BP ↓

Early TRE — Fasting

VESALIUS-CV (NEJM Nov 2025 · N = 12,257)

Evolocumab added to statin therapy in high-risk primary prevention patients. Median achieved LDL-C: 45 mg/dL.

Outcome

Reduction

Significance

3-Point MACE (CV death, MI, stroke)

−25%

HR 0.75 · p<0.001

Myocardial Infarction

−36%

p<0.001

Total Mortality

−20%

p = 0.03

4-Point MACE

−19%

HR 0.81 · p<0.001

CORALreef Lipids (NEJM Feb 2026 · N = 2,909)

Enlicitide — first once-daily oral PCSK9 inhibitor. LDL reduction matches injectable agents. Safety identical to placebo.

Outcome (24 weeks)

Enlicitide

Placebo

LDL-C

−57.1%

+3.0%

Non-HDL-C

−53.4%

—

ApoB

−50.3%

—

Lp(a)

−28.2%

—

CORE-TIMI 72a/b (NEJM Jan 2026 · N = 1,061)

Olezarsen (APOC3 antisense). Transformative for severe hypertriglyceridemia. Pancreatitis risk cut by 85%. Sustained at 12 months.

Outcome (6 months)

50 mg

80 mg

Pancreatitis Risk Reduction

85%

85% (RR 0.15)

TG Reduction (CORE-72a)

−62.9%

−72.2%

TG Reduction (CORE²-72b)

−49.2%

−54.5%

SPRINGER REVIEW 2026

Confirmed four mechanistically distinct CV pathways activated by fasting — AMPK activation, metabolic switching, autophagy, and circadian alignment — each complementing pharmacotherapy through mechanisms no single drug can replicate.

🧬

Mechanism

Mechanism 1 — AMPK-SIRT1-mTOR Activation

Activates AMPK (energy-sensing), upregulates SIRT1 (mitochondrial function), suppresses mTOR (autophagy). Improves insulin sensitivity and endothelial function independent of LDL. No single approved CV drug replicates this triad.

✔ Unique triad — no pharmacological equivalent available.

🔥

Mechanism

Mechanism 2 — Metabolic Switching & Ketogenesis

Activates lipolysis (mobilizes visceral fat), generates ketone bodies (more efficient myocardial fuel), reduces hepatic glucose output over 24h. Ketones may reduce myocardial oxidative stress in heart failure.

✔ Ketone body production reduces cardiac oxidative stress — no approved drug delivers this.

🧪

Mechanism

Mechanism 3 — Autophagy & Cellular Clearance

Removes damaged organelles, misfolded proteins, and lipotoxic aggregates from cardiomyocytes. Mitophagy clears dysfunctional mitochondria. Inflammasome suppression reduces IL-1β and IL-18.

✔ No approved CV autophagy inducer exists — fasting is the only intervention.

🌙

Mechanism

Mechanism 4 — Circadian Alignment & BP Regulation

Early TRE (eating window ending by 5–6 PM) aligns feeding with circadian biology. Restores nocturnal BP dipping. Reduces sympathetic tone. Meta-analyses: 4–8 mmHg systolic BP reduction additive to antihypertensives.

✔ 4–8 mmHg systolic drop — additive to pharmacotherapy. Strongest fasting CV benefit.

Domain

Pharmacotherapy 2026

Fasting/TRE

Strategy

LDL-C

Evolocumab −55% · Enlicitide −57%

−5–15%

Pharmacotherapy primary

Triglycerides

Olezarsen −50–72%

−20–40%

Additive

Lp(a)

PCSK9i −25–30%

<5% (NS)

Drug required

Blood Pressure

Antihypertensives −10–20 mmHg

Early TRE −4–8 mmHg

Additive

Insulin Sensitivity

Metformin, GLP-1, SGLT2i

TRE +20–30%

Synergistic

Inflammation (CRP)

Colchicine, canakinumab

−15–30%

Complementary

Autophagy

None approved

Unique mechanism

Fasting only

FAQS

Q01

Warfarin — Is fasting safe?

Caution required. Dietary vitamin K changes cause INR fluctuations. Monitor INR weekly initially. Take warfarin at Iftar. Consistent meal composition essential. Contraindicated if INR unstable or thromboembolism history.

CAUTION · Weekly INR

Q02

DOACs (apixaban, rivaroxaban, edoxaban, dabigatran)?

Safer than warfarin with fasting — no dietary interactions. Rivaroxaban 15/20 mg: take with Iftar (requires food). Apixaban/dabigatran: no food requirement. Adequate hydration essential (renally cleared). No adjustment for 16:8 TRE.

GENERALLY SAFE · Rivaroxaban with Iftar

Q03

Heart failure (HFrEF or HFpEF) — Can I fast?

Stable HF (NYHA I–II): appropriate with precautions — increased fluids, loop diuretic dose reduction, daily weight monitoring. NYHA III–IV, recent hospitalization, or high-dose diuretics: contraindicated — risk of decompensation, electrolyte disturbance, AKI.

CONTRAINDICATED in NYHA III–IV

Q04

Atrial fibrillation — Can fasting trigger AF?

Fasting doesn’t directly cause AF but creates precipitating conditions: dehydration, hypokalemia/hypomagnesemia, caffeine withdrawal, sleep disruption. Mitigate with hydration, potassium-rich foods at Iftar/Suhoor, gradual caffeine taper.

MONITOR · Electrolytes & Hydration

Q05

Blood pressure medications — How to adjust?

ACE inhibitors/ARBs once-daily: take at Iftar. Amlodipine: take at Iftar. Bisoprolol/metoprolol succinate: take at Iftar. Metoprolol tartrate: split Iftar + Suhoor. Diuretics: HIGH RISK — shift to Iftar, dose reduction usually required. Monitor BP 2–3×/day first week.

HIGH RISK for Diuretics · Dose Reduction Often Required

Q06

Can fasting replace statins or PCSK9 inhibitors?

Absolutely not. Fasting: 5–15% LDL reduction. Statins: 50–55%; PCSK9i: 55–60%. VESALIUS-CV’s 25% MACE and 36% MI reduction are unreplicable by any fasting protocol. Complementary, not interchangeable.

NEVER REPLACE PHARMACOTHERAPY

Q07

Coronary stents — Is fasting safe?

Stable CAD (≥6 months post-stent) on DAPT: generally appropriate. Take aspirin and P2Y12 inhibitor consistently at Iftar. Contraindicated: recent ACS/stent (<3 months), unstable angina, planned revascularization.

INDIVIDUALIZED ASSESSMENT · Cardiologist Review

Q08

Lp(a) — Does fasting help?

No meaningful effect (<5%, non-significant). Lp(a) is genetically determined. PCSK9 inhibitors: enlicitide −28%, evolocumab −25–30%. Statins: neutral to slightly increase. Patients with Lp(a) >50 mg/dL must rely on PCSK9i, not fasting.

PHARMACOTHERAPY REQUIRED for Lp(a)

Q09

Metabolic syndrome — Can fasting help?

Strong evidence — this is fasting’s primary CV indication. Early TRE (14:10 or 16:8, window ending by 5–6 PM) for 12 weeks: waist circumference ↓, triglycerides −20–40%, HDL-C +5–10%, systolic BP −4–8 mmHg, fasting glucose −5–15 mg/dL.

STRONG EVIDENCE · Primary Fasting Indication

Q10

Bottom line — How to combine fasting with CV medications?

Safe: statins, PCSK9i, GLP-1 agonists, aspirin, ezetimibe. Monitor: DOACs (Iftar for rivaroxaban), beta-blockers (split doses), antiarrhythmics (consistent timing). High caution: diuretics (dose reduction + Iftar), warfarin (weekly INR). Avoid: SGLT2i with fasts >24h (DKA risk); insulin (reduce basal 10–20%, CGM); sulfonylureas (reduce or hold).

INDIVIDUALIZED MEDICATION REVIEW REQUIRED

✔ SAFE

⚠ MONITOR

! CAUTION

✗ HIGH RISK

· Statins (take at Iftar)

· PCSK9 inhibitors (maintain schedule)

· GLP-1 agonists (take at Iftar)

· Aspirin & Ezetimibe (take at Iftar)

· DOACs (Rivaroxaban with Iftar)

· Beta-blockers (split or Iftar)

· ACE inhibitors / ARBs (Iftar)

· Antiarrhythmics (consistent timing)

· Warfarin (weekly INR monitoring)

· SGLT2i (hold for fasts >24h — DKA risk)

· Loop/Thiazide diuretics (dose reduction + Iftar)

· Insulin (reduce basal 10–20%, CGM)

· Sulfonylureas (reduce or hold)

✓ MAY BE APPROPRIATE

· Stable CAD

· Controlled hypertension

· Metabolic syndrome

· T2DM (well-controlled)

· AF (rate-controlled)

· Hypertriglyceridemia (mild)

⚠ HIGH CAUTION

· HFrEF (EF <40%)

· CKD Stage 3–4

· High-dose diuretics

· On SGLT2 inhibitors

· Labile INR (warfarin)

· On insulin

✗ CONTRAINDICATED

· Recent MI/stroke (<3 mo)

· NYHA III–IV HF

· Unstable angina

· Recent PCI/CABG (<3 mo)

· Severe valve disease

· Eating disorder history

FOR LDL-C

Pharmacotherapy primary (PCSK9i + statin: 55–60% reduction). Fasting adjunctive (+5–15%). VESALIUS-CV’s event reduction is unreplicable by lifestyle alone.

FOR TRIGLYCERIDES

Olezarsen transformative for severe cases (50–72% reduction, 85% pancreatitis risk reduction). TRE adds 20–40% in moderate hypertriglyceridemia.

FOR HYPERTENSION & INSULIN RESISTANCE

Early TRE (16:8, eating window ending 5–6 PM) adds 4–8 mmHg systolic BP drop and 20–30% insulin sensitivity improvement. Strongest fasting CV value.

FOR Lp(a)

Fasting: <5%, non-significant. PCSK9 inhibitors: −25–30%. Patients with Lp(a) >50 mg/dL must rely on pharmacotherapy — not fasting.

THE 2026 BOTTOM LINE

2026 is the year cardiovascular medicine and fasting science converge. New pharmacotherapies achieve unprecedented lipid and triglyceride reductions. Fasting validates lifestyle interventions through complementary mechanisms. The integrated approach — personalized pharmacotherapy plus structured, supervised fasting — offers the most powerful cardiovascular prevention strategy to date.

“The best cardiovascular prevention strategy is the one that is evidence-based, individually tailored, safely implemented, and sustainably maintained.” — H-K-E-M Medical Research, March 2026

⚕️ MEDICAL DISCLAIMER

This document is published for educational and informational purposes only. It reflects peer-reviewed research and clinical guidelines as of March 2026. It does not constitute medical advice, diagnosis, or treatment recommendation. No content should be used as the basis for starting, stopping, or modifying any cardiovascular medication, diabetes management plan, or fasting protocol without prior consultation with a qualified cardiologist, endocrinologist, and diabetes care team.

VESALIUS-CV (NEJM, Nov 2025) · CORALreef Lipids (NEJM, Feb 2026) · CORE-TIMI 72a/b (NEJM, Jan 2026) · ACC/AHA 2026 Guidelines · Springer Fasting Review 2026 · ADA 2026

H-K-E-M Medical Research · March 2026 · Summary Infology Edition

==================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================

==================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================

==================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================